PAMS
SAGE

Pictet Asset Management (Switzerland)’s Sage Therapeutics SAGE Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$28.2M Buy
598,918
+592,380
+9,061% +$29.5M 0.03% 387
2023
Q1 		$274K Hold
6,538
– – ﹤0.01% 1552
2022
Q4 		$249K Buy
+6,538
New +$250K ﹤0.01% 1603

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s SAGE Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Sage Therapeutics (SAGE) stake by 9,061% in Q2 2023, buying an estimated $29.5M and bringing the position to 598,918 shares worth $28.2M. The position accounts for 0.03% of the portfolio, ranked #387.

Pictet Asset Management (Switzerland) first reported a position in SAGE in Q4 2022 and has held it in 3 quarters since. 225 funds tracked by Wall St. Rank hold SAGE as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 598,918 shares of Sage Therapeutics worth $28.2M as of Q2 2023.
  • Pictet Asset Management (Switzerland) bought 592,380 Sage Therapeutics shares in Q2 2023, an estimated $29.5M.
  • Sage Therapeutics made up 0.03% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #387 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Sage Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • 225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.